David V. Elkins
Summary
David V. Elkins has been Bristol Myers Squibb’s executive vice president and chief financial officer since November 2019, following his service as Celgene’s CFO. ([bms.com](https://www.bms.com/our-company/leadership/leadership-team/david-elkins.html?utm_source=openai))
Biography
Elkins leads BMS’s Global Business Operations organization, which includes finance, business development, global financial services and operational excellence, procurement, and investor relations. He joined BMS through its acquisition of Celgene, where he had served as executive vice president and CFO beginning in 2018. ([bms.com](https://www.bms.com/our-company/leadership/leadership-team/david-elkins.html?utm_source=openai)) Before Celgene, Elkins held senior finance roles at Johnson & Johnson, including CFO responsibilities for consumer products, medical devices and corporate functions. He was also executive vice president and CFO of Becton, Dickinson and Company and held progressively senior roles at AstraZeneca from 1995 to 2008. He began his finance career at The Boeing Company and holds degrees from the University of Delaware, the University of Pennsylvania and Drexel University. ([bms.com](https://www.bms.com/our-company/leadership/leadership-team/david-elkins.html?utm_source=openai))
Notable achievements
- Helped lead BMS’s finance organization through the completion and integration of the Celgene acquisition. ([news.bms.com](https://news.bms.com/news/corporate-financial/2019/Bristol-Myers-Squibb-Announces-Post-Closing-Leadership-Team/default.aspx?utm_source=openai))
- Maintains responsibility for finance, procurement, investor relations and business-development support across the combined company. ([bms.com](https://www.bms.com/our-company/leadership/leadership-team/david-elkins.html?utm_source=openai))
- Has overseen financial planning and capital-allocation processes during a period of major acquisitions and portfolio expansion. ([bms.com](https://www.bms.com/our-company/leadership/leadership-team/david-elkins.html?utm_source=openai))
- BMS reported $48.2 billion in 2025 revenue while continuing to invest heavily in research and development and newer products. ([bms.com](https://www.bms.com/investors/financial-reporting/key-facts.html?utm_source=openai))
Problem areas / controversies
- BMS carries significant financial and integration demands from the Celgene transaction and subsequent acquisitions, increasing pressure on returns and balance-sheet management. ([axios.com](https://www.axios.com/2019/01/03/bristol-myers-squibb-buying-celgene-74-billion?utm_source=openai))
- The company’s finance function must manage declining Revlimid sales and future exclusivity pressure on major products such as Eliquis and Opdivo. ([sec.gov](https://www.sec.gov/Archives/edgar/data/14272/000001427225000039/bmy-20241231.htm?utm_source=openai))
- Cost-reduction programs and workforce reductions have been part of BMS’s response to the patent-cliff and productivity pressures, which can create organizational disruption. ([fortune.com](https://fortune.com/article/bristol-myers-squibb-ceo-chris-boerner-patent-cliff-company-culture/?utm_source=openai))
- No major personal regulatory, accounting or ethics controversy involving Elkins was identified in the reviewed public filings and reputable coverage.